Mark Jason H. Ellison
Direktor/Vorstandsmitglied bei Phax Pharma Consultants
Profil
Mark Jason H.
Ellison is currently the Director at Phax Pharma Consultants and a Member at GPhC.
He was previously the Chief Development Officer at Opiant Pharmaceuticals, Inc. from 2020 to 2023 and the Head-Technical Affairs at S.L.A.
Pharma AG from 2010 to 2014.
Ellison holds a doctorate degree from the University of Sunderland and an undergraduate degree from the University of Portsmouth.
Aktive Positionen von Mark Jason H. Ellison
| Unternehmen | Position | Beginn |
|---|---|---|
| GPhC | Corporate Officer/Principal | - |
| Phax Pharma Consultants | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Mark Jason H. Ellison
| Unternehmen | Position | Ende |
|---|---|---|
| OPIANT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 02.03.2023 |
S.L.A. Pharma AG
 S.L.A. Pharma AG BiotechnologyHealth Technology S.L.A. Pharma AG engages in the manufacture of pharmaceutical products. It specializes in development of medicines for the prevention and treatment of gastrointestinal disorders. The company was founded in 1997 and is headquartered in Liestal, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2014 |
Ausbildung von Mark Jason H. Ellison
| University of Portsmouth | Undergraduate Degree |
| University of Sunderland | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Opiant Pharmaceuticals, Inc.
 Opiant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA. | Health Technology |
S.L.A. Pharma AG
S.L.A. Pharma AG BiotechnologyHealth Technology S.L.A. Pharma AG engages in the manufacture of pharmaceutical products. It specializes in development of medicines for the prevention and treatment of gastrointestinal disorders. The company was founded in 1997 and is headquartered in Liestal, Switzerland. | Health Technology |
| GPhC | |
| Phax Pharma Consultants |
